Ruiying Chen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ruiying Chen has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Cheng Peng
Department of Obstetrics and Gynaecology, Nanfang Hospital, Southern Medical University, Guangzhou, China
1 shared publication- Chunlin Chen
Department of Obstetrics and Gynecology, Nanfang Hospital, Southern Medical University, Guangzhou, China
1 shared publication Guangliang Li
Department of ENT, The First Hospital of Wenzhou Medical University, Wenzhou, China
1 shared publication- Haiyan Zhu
Shanghai Key Laboratory of Maternal Fetal Medicine, Shanghai Institute of Maternal-Fetal Medicine and Gynecologic Oncology, Shanghai First Maternity and Infant Hospital, School of Medicine, Tongji University, Shanghai, China
1 shared publication - Hao Wu
Chashan Teaching Centre, Department of Physiology, Wenzhou Medical University, Wenzhou, 325035, Zhejiang, China
1 shared publication Kedan Liao
Department of Obstetrics and Gynaecology, Nanfang Hospital, Southern Medical University, Guangzhou, China
1 shared publication
Latest Publications
- Open Access
- 1 August 2023
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (15) , 13727-13739
Development and validation of nomograms to recurrence and survival in patients with early-stage cervical adenocarcinoma
Purpose: Cervical adenocarcinoma is one of the most common types of cervical cancer and its incidence is increasing. The biological behavior and treatment outcomes of cervical adenocarcinoma (CA) differ from those of squamous cell carcinoma (SCC). We sought to develop a model to predict recurrence and cancer-specific survival (CSS) deaths in CA patients. Methods: 131 patients were included in model development and internal validation, and patients from the SEER database (N = 1679) were used for external validation. Multivariable Cox proportional hazards regression analysis was used to select predictors of relapse-free survival (RFS) and CSS and to construct the model, which was presented as two nomograms. Internal validation of the nomograms was performed using the bootstrap resampling method. Results: Age, FIGO (International Federation of Gynecology and Obstetrics) stage, size of the tumor, lymph metastasis and depth of invasion were identified as independent prognostic factors for RFS, while age, FIGO stage, size of the tumor and number of positive LNs were identified as independent prognostic factors for CSS. The nomogram of the recurrence model predicted 2- and 5-year RFS, with optimism adjusted c-statistic of 75.41% and 74.49%. Another nomogram predicted the 2- and 5-year CSS with an optimism-adjusted c-statistic of 83.22% and 83.31% after internal validation; and 68.6% and 71.33% after external validation. Conclusions: We developed and validated two effective nomograms based on static nomograms or online calculators that can help clinicians quantify the risk of relapse and death for patients with early-stage CA.
- 1 August 2023
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 149 (15) , 13727-13739
Open AccessDevelopment and validation of nomograms to recurrence and survival in patients with early-stage cervical adenocarcinoma
Purpose: Cervical adenocarcinoma is one of the most common types of cervical cancer and its incidence is increasing. The biological behavior and treatment outcomes of cervical adenocarcinoma (CA) differ from those of squamous cell carcinoma (SCC). We sought to develop a model to predict recurrence and cancer-specific survival (CSS) deaths in CA patients. Methods: 131 patients were included in model development and internal validation, and patients from the SEER database (N = 1679) were used for external validation. Multivariable Cox proportional hazards regression analysis was used to select predictors of relapse-free survival (RFS) and CSS and to construct the model, which was presented as two nomograms. Internal validation of the nomograms was performed using the bootstrap resampling method. Results: Age, FIGO (International Federation of Gynecology and Obstetrics) stage, size of the tumor, lymph metastasis and depth of invasion were identified as independent prognostic factors for RFS, while age, FIGO stage, size of the tumor and number of positive LNs were identified as independent prognostic factors for CSS. The nomogram of the recurrence model predicted 2- and 5-year RFS, with optimism adjusted c-statistic of 75.41% and 74.49%. Another nomogram predicted the 2- and 5-year CSS with an optimism-adjusted c-statistic of 83.22% and 83.31% after internal validation; and 68.6% and 71.33% after external validation. Conclusions: We developed and validated two effective nomograms based on static nomograms or online calculators that can help clinicians quantify the risk of relapse and death for patients with early-stage CA.
- Retracted
- 31 May 2019
- Published by Wiley in Clinical Otolaryngology
- Vol. 44 (5) , 757-761
Retracted: Increased maternal serum placental growth hormone variant in pregnancies complicated by otosclerosis
Objective: To investigate the potential role of maternal serum concentrations of placental growth hormone variant (GH‐V), insulin‐like growth factor (IGF) 1 and 2, and IGF‐binding proteins (IGFBP) 1 and 3 in pregnancies complicated by otosclerosis.Method: Otosclerosis cases (n = 22) and age, ethnicity‐matched controls (n = 22) were selected in a nested case‐control study. Maternal serum hormone concentrations at 26 and 34 weeks of gestation were determined by enzyme‐linked immunosorbent assay (ELISA).Results: Concentrations of all measured hormones except IGFBP‐1 were increased as gestation progressed. Maternal serum GH‐V concentrations at 26 and 34 weeks of gestation were significantly increased in the otosclerosis group, when compared to the control group (2.53 ± 0.17 ng/ml vs. 1.78 ± 0.19 ng/ml, P = 0.036; 4.34 ± 0.31 ng/ml vs. 3.12 ± 0.18 ng/ml, P < 0.001, respectively). Maternal serum IGF‐1 concentrations at 34 weeks in otosclerotic patients were significantly higher than in the controls (589.1 ± 21.4 ng/ml vs. 499.7 ± 17.8 ng/ml, P < 0.001). The increase of IGF‐1 was not observed at 26 weeks of gestation. Serum IGF‐2, IGFBP‐1 and IGFBP‐3 at either 26 or 34 weeks were unaltered between the two groups.Conclusion: Maternal serum concentrations of GH‐V and IGF‐1 were altered in pregnancy complicated by otosclerosis, suggesting that the GH‐IGF axis may contribute to the development of this condition during pregnancy.
- 31 May 2019
- Published by Wiley in Clinical Otolaryngology
- Vol. 44 (5) , 757-761
RetractedRetracted: Increased maternal serum placental growth hormone variant in pregnancies complicated by otosclerosis
Objective: To investigate the potential role of maternal serum concentrations of placental growth hormone variant (GH‐V), insulin‐like growth factor (IGF) 1 and 2, and IGF‐binding proteins (IGFBP) 1 and 3 in pregnancies complicated by otosclerosis.Method: Otosclerosis cases (n = 22) and age, ethnicity‐matched controls (n = 22) were selected in a nested case‐control study. Maternal serum hormone concentrations at 26 and 34 weeks of gestation were determined by enzyme‐linked immunosorbent assay (ELISA).Results: Concentrations of all measured hormones except IGFBP‐1 were increased as gestation progressed. Maternal serum GH‐V concentrations at 26 and 34 weeks of gestation were significantly increased in the otosclerosis group, when compared to the control group (2.53 ± 0.17 ng/ml vs. 1.78 ± 0.19 ng/ml, P = 0.036; 4.34 ± 0.31 ng/ml vs. 3.12 ± 0.18 ng/ml, P < 0.001, respectively). Maternal serum IGF‐1 concentrations at 34 weeks in otosclerotic patients were significantly higher than in the controls (589.1 ± 21.4 ng/ml vs. 499.7 ± 17.8 ng/ml, P < 0.001). The increase of IGF‐1 was not observed at 26 weeks of gestation. Serum IGF‐2, IGFBP‐1 and IGFBP‐3 at either 26 or 34 weeks were unaltered between the two groups.Conclusion: Maternal serum concentrations of GH‐V and IGF‐1 were altered in pregnancy complicated by otosclerosis, suggesting that the GH‐IGF axis may contribute to the development of this condition during pregnancy.
- 1 January 2019
- Published by Elsevier in European Journal of Radiology
- Vol. 110, 242-248
A modified model can improve the accuracy of foetal weight estimation by magnetic resonance imaging
- 1 January 2019
- Published by Elsevier in European Journal of Radiology
- Vol. 110, 242-248
A modified model can improve the accuracy of foetal weight estimation by magnetic resonance imaging
- Open Access
- 15 September 2018
- Published by XMLink in Clinical Hypertension
- Vol. 24 (1) , 11
Apolipoprotein A1 mimetic peptide ATI-5261 reverses arterial stiffness at late pregnancy and early postpartum in a COMT−/− mouse model of preeclampsia
Preeclampsia (PE) is a serious maternal complication during pregnancy. Associated arterial stiffness in PE patients leads to increased risks of cardiovascular diseases later in life. Cholesterol efflux capacity, especially ATP binding cassette transporter A1 (ABCA1) dependent capacity, has been proposed to be a likely mediator of arterial stiffness. In the present study, we aimed to evaluate the effect of an apolipoprotein A1 mimetic peptide ATI-5261 on arterial stiffness in a mouse model of PE. Pregnant COMT−/− mice were randomized to receive vehicle or ATI-5261 (30 mg/kg per day) via subcutaneous injection from gestational days (GD) 10.5 to GD 18.5 or to 10 days postpartum. Pregnant C57BL/6 J mice received vehicle during paralleled periods were served as normal controls. COMT−/− mice displayed maternal hypertension and proteinuria during pregnancy. Carotid–femoral pulse wave velocity (PWV) was increased at GD 18.5 and 10 days postpartum. ATI-5261 treatment in COMT−/− mice significantly reduced PWV and partially normalized impaired ex vivo vascular function at late pregnancy and early postpartum. ATI-5261 treatment also increased serum ABCA1 concentrations and cholesterol efflux capacity, as well as ABCA1 expressions in the placenta. Pup weights, crown to rump lengths and abdominal circumferences were reduced in COMT−/− mice. Treatment with ATI-5261 did not alter these fetal measurements but significantly reduced placental weights and increased fetal to placental ratios in COMT−/− mice. ATI-5261 reversed arterial stiffness at late pregnancy and early postpartum in a COMT−/− mouse model of PE and may be a potential therapy for arterial stiffness associated with PE.
- 15 September 2018
- Published by XMLink in Clinical Hypertension
- Vol. 24 (1) , 11
Open AccessApolipoprotein A1 mimetic peptide ATI-5261 reverses arterial stiffness at late pregnancy and early postpartum in a COMT−/− mouse model of preeclampsia
Preeclampsia (PE) is a serious maternal complication during pregnancy. Associated arterial stiffness in PE patients leads to increased risks of cardiovascular diseases later in life. Cholesterol efflux capacity, especially ATP binding cassette transporter A1 (ABCA1) dependent capacity, has been proposed to be a likely mediator of arterial stiffness. In the present study, we aimed to evaluate the effect of an apolipoprotein A1 mimetic peptide ATI-5261 on arterial stiffness in a mouse model of PE. Pregnant COMT−/− mice were randomized to receive vehicle or ATI-5261 (30 mg/kg per day) via subcutaneous injection from gestational days (GD) 10.5 to GD 18.5 or to 10 days postpartum. Pregnant C57BL/6 J mice received vehicle during paralleled periods were served as normal controls. COMT−/− mice displayed maternal hypertension and proteinuria during pregnancy. Carotid–femoral pulse wave velocity (PWV) was increased at GD 18.5 and 10 days postpartum. ATI-5261 treatment in COMT−/− mice significantly reduced PWV and partially normalized impaired ex vivo vascular function at late pregnancy and early postpartum. ATI-5261 treatment also increased serum ABCA1 concentrations and cholesterol efflux capacity, as well as ABCA1 expressions in the placenta. Pup weights, crown to rump lengths and abdominal circumferences were reduced in COMT−/− mice. Treatment with ATI-5261 did not alter these fetal measurements but significantly reduced placental weights and increased fetal to placental ratios in COMT−/− mice. ATI-5261 reversed arterial stiffness at late pregnancy and early postpartum in a COMT−/− mouse model of PE and may be a potential therapy for arterial stiffness associated with PE.